Biaolong Yang1, Biaolong Deng2, Xiao-Dong Jiao1, Bao-Dong Qin1, Yi Lu3, Weiqi Zhang2, Yixian Guo4, Shiqi Chen1, Dan Li2, Bin Li5, Yuan-Sheng Zang6. 1. Department of Oncology, Changzheng Hospital, Naval Medical University, 200003, Shanghai, China. 2. Department of Immunology and Microbiology, Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, China. 3. Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 200011, Shanghai, China. 4. Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, 200127, Shanghai, China. 5. Department of Immunology and Microbiology, Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, China. binli@shsmu.edu.cn. 6. Department of Oncology, Changzheng Hospital, Naval Medical University, 200003, Shanghai, China. doctorzangys@163.com.
Abstract
PURPOSE: Our study intended to explore how low-dose anti-angiogenic drugs affected anti-tumor immunity of tumor-infiltrating exhausted CD8+T cells and achieved better clinical response when combined with immunotherapy. We set out to find potential targets or predictive biomarker on CD8+T cells for immunotherapy. METHODS: We tested different doses of anti-VEGFR2 antibody combined with anti-PD1 antibody to treat LUAD in vivo and analyzed tumor-infiltrating CD8+T cells by flow cytometry. CD8+T cells overexpressing LAYN were co-cultured with LA795 cell lines to identify the function of LAYN in CD8+T cells. We also analyzed clinical samples from advanced LUAD patients treated with anti-angiogenesis therapy combined with immunotherapy. RESULTS: Low-dose anti-VEGFR2 antibody combined with anti-PD1 antibody treatment delayed tumor growth and prolonged the survival time of tumor-bearing mice. The number of tumor-infiltrating CD8+T cells was reduced and the expression of LAYN was down-regulated in tumor-infiltrating CD8+T cells in the low-dose anti-VEGFR2 combination group. It was found that LAYN inhibited the killing function of CD8+T cells. In patients with advanced LUAD who received anti-angiogenesis therapy combined with immunotherapy, the LAYN+CD8+T cell subpopulation in good responders was significantly higher than that in poor responders. Furthermore, we demonstrated the expression of LAYN was regulated by upstream transcription factor NR4A1. CONCLUSION: Low-dose anti-VEGFR2 antibody combined with anti-PD1 antibody therapy promoted anti-tumor immunity and the downregulation of LAYN in tumor-infiltrating CD8+T cells played an important role in this process. These findings had implications for improving the efficacy of immune checkpoint blockade therapy and further optimized clinical treatment guidelines in advanced LUAD.
PURPOSE: Our study intended to explore how low-dose anti-angiogenic drugs affected anti-tumor immunity of tumor-infiltrating exhausted CD8+T cells and achieved better clinical response when combined with immunotherapy. We set out to find potential targets or predictive biomarker on CD8+T cells for immunotherapy. METHODS: We tested different doses of anti-VEGFR2 antibody combined with anti-PD1 antibody to treat LUAD in vivo and analyzed tumor-infiltrating CD8+T cells by flow cytometry. CD8+T cells overexpressing LAYN were co-cultured with LA795 cell lines to identify the function of LAYN in CD8+T cells. We also analyzed clinical samples from advanced LUAD patients treated with anti-angiogenesis therapy combined with immunotherapy. RESULTS: Low-dose anti-VEGFR2 antibody combined with anti-PD1 antibody treatment delayed tumor growth and prolonged the survival time of tumor-bearing mice. The number of tumor-infiltrating CD8+T cells was reduced and the expression of LAYN was down-regulated in tumor-infiltrating CD8+T cells in the low-dose anti-VEGFR2 combination group. It was found that LAYN inhibited the killing function of CD8+T cells. In patients with advanced LUAD who received anti-angiogenesis therapy combined with immunotherapy, the LAYN+CD8+T cell subpopulation in good responders was significantly higher than that in poor responders. Furthermore, we demonstrated the expression of LAYN was regulated by upstream transcription factor NR4A1. CONCLUSION: Low-dose anti-VEGFR2 antibody combined with anti-PD1 antibody therapy promoted anti-tumor immunity and the downregulation of LAYN in tumor-infiltrating CD8+T cells played an important role in this process. These findings had implications for improving the efficacy of immune checkpoint blockade therapy and further optimized clinical treatment guidelines in advanced LUAD.
Authors: Leisha A Emens; Paolo A Ascierto; Phillip K Darcy; Sandra Demaria; Alexander M M Eggermont; William L Redmond; Barbara Seliger; Francesco M Marincola Journal: Eur J Cancer Date: 2017-06-15 Impact factor: 9.162
Authors: Christian Manegold; Anne-Marie C Dingemans; Jhanelle E Gray; Kazuhiko Nakagawa; Marianne Nicolson; Solange Peters; Martin Reck; Yi-Long Wu; Odd Terje Brustugun; Lucio Crinò; Enriqueta Felip; Dean Fennell; Pilar Garrido; Rudolf M Huber; Aurélien Marabelle; Marcin Moniuszko; Françoise Mornex; Silvia Novello; Mauro Papotti; Maurice Pérol; Egbert F Smit; Kostas Syrigos; Jan P van Meerbeeck; Nico van Zandwijk; James Chih-Hsin Yang; Caicun Zhou; Everett Vokes Journal: J Thorac Oncol Date: 2016-10-08 Impact factor: 15.609
Authors: Eric Tartour; H Pere; B Maillere; M Terme; N Merillon; J Taieb; F Sandoval; F Quintin-Colonna; K Lacerda; A Karadimou; C Badoual; A Tedgui; W H Fridman; S Oudard Journal: Cancer Metastasis Rev Date: 2011-03 Impact factor: 9.264
Authors: Yuhui Huang; Jianping Yuan; Elda Righi; Walid S Kamoun; Marek Ancukiewicz; Jean Nezivar; Michael Santosuosso; John D Martin; Margaret R Martin; Fabrizio Vianello; Pierre Leblanc; Lance L Munn; Peigen Huang; Dan G Duda; Dai Fukumura; Rakesh K Jain; Mark C Poznansky Journal: Proc Natl Acad Sci U S A Date: 2012-10-08 Impact factor: 11.205
Authors: F Stephen Hodi; Donald Lawrence; Cecilia Lezcano; Xinqi Wu; Jun Zhou; Tetsuro Sasada; Wanyong Zeng; Anita Giobbie-Hurder; Michael B Atkins; Nageatte Ibrahim; Philip Friedlander; Keith T Flaherty; George F Murphy; Scott Rodig; Elsa F Velazquez; Martin C Mihm; Sara Russell; Pamela J DiPiro; Jeffrey T Yap; Nikhil Ramaiya; Annick D Van den Abbeele; Maria Gargano; David McDermott Journal: Cancer Immunol Res Date: 2014-04-21 Impact factor: 11.151
Authors: Jeffrey J Wallin; Johanna C Bendell; Roel Funke; Mario Sznol; Konstanty Korski; Suzanne Jones; Genevive Hernandez; James Mier; Xian He; F Stephen Hodi; Mitchell Denker; Vincent Leveque; Marta Cañamero; Galina Babitski; Hartmut Koeppen; James Ziai; Neeraj Sharma; Fabien Gaire; Daniel S Chen; Daniel Waterkamp; Priti S Hegde; David F McDermott Journal: Nat Commun Date: 2016-08-30 Impact factor: 14.919